NCT01639352View on ClinicalTrials.gov

Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

February 28, 2017

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

SOM230

Patients will be given a starting of 60mg of SOM230 via injection, intramuscularly every 28 days.

Trial Locations (1)

33136

University of Miami, Miami

All Listed Sponsors
lead

Lynn Feun

OTHER

NCT01639352 - Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter